The rationale for neoadjuvant radiation therapy in malignant pleural mesothelioma: how smart is SMART?

por Cho, B. C. John
Publicado en Ann Transl Med (2017)

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

por Westover, D, Zugazagoitia, J, Cho, B C, Lovly, C M, Paz-Ares, L
Publicado en Ann Oncol (2018)

Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer

por Yung, T., Giuliani, M.E., Le, L.W., Sun, A., Cho, B.C.J., Bezjak, A., Brade, A., Hope, A.J.
Publicado 2012

Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas.

por Cho, B C, Shaughnessy, J D, Largaespada, D A, Bedigian, H G, Buchberg, A M, Jenkins, N A, Copeland, N G
Publicado 1995

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens

por Jeung, H-C, Rha, S Y, Cho, B C, Yoo, N C, Roh, J K, Roh, W J, Chung, H C, Ahn, J B
Publicado 2006

Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy

por Giuliani, M., Sampson, L.R., Wong, O., Gay, J., Le, L.W., Cho, B.C.J., Brade, A., Sun, A., Bezjak, A., Hope, A.J.
Publicado en Curr Oncol (2016)

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy

por Kim, S-M, Kim, H, Yun, M R, Kang, H N, Pyo, K-H, Park, H J, Lee, J M, Choi, H M, Ellinghaus, P, Ocker, M, Paik, S, Kim, H R, Cho, B C
Publicado en Oncogenesis (2016)

Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy

por Tagawa, Tetsuzo, Anraku, Masaki, Morodomi, Yosuke, Takenaka, Tomoyoshi, Okamoto, Tatsuro, Takenoyama, Mitsuhiro, Ichinose, Yukito, Maehara, Yoshihiko, Cho, B. C. John, Feld, Ronald, Tsao, Ming-Sound, Leighl, Natasha, Bezjak, Andrea, Keshavjee, Shaf, de Perrot, Marc
Publicado en J Thorac Dis (2015)

Dabrafenib in BRAF V600E–Mutant Advanced Non-Small Cell Lung Cancer: an Open-label, Single arm, Multicenter, Phase 2 Trial

por Planchard, David, Kim, Tae Min, Mazieres, Julien, Quoix, Elisabeth, Riely, Gregory, Barlesi, Fabrice, Souquet, Pierre-John, Smit, Egbert F., Groen, Harry J. M., Kelly, Ronan J., Cho, B. C., Socinski, Mark A., Pandite, Lini, Nase, Christine, Ma, Bo, D’Amelio, Anthony, Mookerjee, Bijoyesh, Curtis, C. Martin, Johnson, Bruce E.
Publicado en Lancet Oncol (2016)

A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted Analysis

por Yan, Michael, Sigurdson, Samantha, Greifer, Noah, Kennedy, Thomas A. C., Toh, Tzen S., Lindsay, Patricia E., Weiss, Jessica, Hueniken, Katrina, Yeung, Christy, Sugumar, Vijithan, Sun, Alexander, Bezjak, Andrea, Cho, B. C. John, Raman, Srinivas, Hope, Andrew J., Giuliani, Meredith E., Stuart, Elizabeth A., Owen, Timothy, Ashworth, Allison, Robinson, Andrew, de Moraes, Fabio Ynoe, Liu, Geoffrey, Lok, Benjamin H.
Publicado en Cancers (Basel) (2021)